Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Net Income (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed Net Income for 5 consecutive years, with -$19.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Income rose 75.8% year-over-year to -$19.9 million, compared with a TTM value of -$24.2 million through Dec 2025, up 81.56%, and an annual FY2025 reading of -$24.2 million, up 81.56% over the prior year.
  • Net Income was -$19.9 million for Q4 2025 at Aligos Therapeutics, up from -$31.5 million in the prior quarter.
  • Across five years, Net Income topped out at $43.1 million in Q1 2025 and bottomed at -$82.1 million in Q4 2024.
  • Average Net Income over 5 years is -$23.4 million, with a median of -$22.4 million recorded in 2022.
  • Peak annual rise in Net Income hit 223.59% in 2025, while the deepest fall reached 413.44% in 2025.
  • Year by year, Net Income stood at -$37.7 million in 2021, then soared by 41.97% to -$21.9 million in 2022, then fell by 27.44% to -$27.9 million in 2023, then plummeted by 194.53% to -$82.1 million in 2024, then skyrocketed by 75.8% to -$19.9 million in 2025.
  • Business Quant data shows Net Income for ALGS at -$19.9 million in Q4 2025, -$31.5 million in Q3 2025, and -$15.9 million in Q2 2025.